JP2005519876A - ２−アミノキノリン化合物 - Google Patents

２−アミノキノリン化合物 Download PDF

Info

Publication number
JP2005519876A
JP2005519876A JP2003546818A JP2003546818A JP2005519876A JP 2005519876 A JP2005519876 A JP 2005519876A JP 2003546818 A JP2003546818 A JP 2003546818A JP 2003546818 A JP2003546818 A JP 2003546818A JP 2005519876 A JP2005519876 A JP 2005519876A
Authority
JP
Japan
Prior art keywords
quinolin
trifluoromethyl
phenyl
alkyl
propanamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003546818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519876A5 (enExample
Inventor
デビータ，ロバート・ジエイ
チヤン，ルーホワ
チヤウン，ダニー
ホアン，ミレー
ジヤン，ジンロン
リン，ピーター
ザイラー，アンドレアス・ダブリユー
ヤング，ジヨナサン・アール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2005519876A publication Critical patent/JP2005519876A/ja
Publication of JP2005519876A5 publication Critical patent/JP2005519876A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
JP2003546818A 2001-11-27 2002-11-22 ２−アミノキノリン化合物 Pending JP2005519876A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33358101P 2001-11-27 2001-11-27
PCT/US2002/037556 WO2003045313A2 (en) 2001-11-27 2002-11-22 2-aminoquinoline compounds

Publications (2)

Publication Number Publication Date
JP2005519876A true JP2005519876A (ja) 2005-07-07
JP2005519876A5 JP2005519876A5 (enExample) 2006-01-05

Family

ID=23303394

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003546818A Pending JP2005519876A (ja) 2001-11-27 2002-11-22 ２−アミノキノリン化合物

Country Status (6)

Country Link
US (1) US7084156B2 (enExample)
EP (1) EP1450801A4 (enExample)
JP (1) JP2005519876A (enExample)
AU (1) AU2002352878B2 (enExample)
CA (1) CA2468015A1 (enExample)
WO (1) WO2003045313A2 (enExample)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526723A (ja) * 2002-02-15 2005-09-08 グラクソ　グループ　リミテッド バニロイド受容体モジュレーター
JPWO2004103992A1 (ja) * 2003-05-21 2006-07-20 萬有製薬株式会社 ２−アミノキノリン誘導体
WO2009011336A1 (ja) * 2007-07-18 2009-01-22 Taisho Pharmaceutical Co., Ltd. キノリン化合物
JP2009526793A (ja) * 2006-02-15 2009-07-23 サノフィ−アベンティス 新規なアザシクリル置換アリールジヒドロイソキノリノン、それらの製造方法及び薬剤としてそれらの使用
JP2010504939A (ja) * 2006-09-28 2010-02-18 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ結合性を有するキノリン誘導体
JP2010540483A (ja) * 2007-09-27 2010-12-24 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ５ａ受容体アンタゴニストとしてのキノリン誘導体
JP2011513350A (ja) * 2008-03-05 2011-04-28 エフ．ホフマン−ラ ロシュ アーゲー ２−アミノキノリン類
JP2011513452A (ja) * 2008-03-12 2011-04-28 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ５ａ受容体アンタゴニストとしての２−アミノキノリン
JP2011518809A (ja) * 2008-04-24 2011-06-30 アボット ゲーエムベーハー ウント カンパニー カーゲー グリコーゲン合成酵素キナーゼ３（ｇｓｋ−３）としての１−（７−（ヘキサヒドロピロロ［３，４−ｃ］ピロール−２（１ｈ）−イル）キノリン−４−イル）−３−（ピラジン−２−イル）尿素誘導体とその関連化合物
JP2012528078A (ja) * 2009-05-29 2012-11-12 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体
WO2014034719A1 (ja) * 2012-08-29 2014-03-06 興和株式会社 Ｔｌｒ阻害作用を有するキノリン誘導体
JP2023532332A (ja) * 2020-07-02 2023-07-27 リミックス セラピューティクス インコーポレイテッド 核酸のスプライシング及び増殖性疾患の処置のためのモジュレーターとしての２－（インダゾール－５－イル）－６－（ピペリジン－４－イル）－１，７－ナフチリジン誘導体及び関連する化合物

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US6989392B2 (en) 2002-06-18 2006-01-24 Abbott Laboratories 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
WO2004002531A1 (ja) * 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. 血管の収縮または拡張による疾患治療剤
WO2004011440A1 (ja) * 2002-07-30 2004-02-05 Banyu Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
US7351719B2 (en) * 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
AU2003287878A1 (en) * 2002-12-11 2004-06-30 7Tm Pharma A/S Quinoline compounds for use in mch receptor related disorders
CA2515717A1 (en) 2003-02-10 2004-08-19 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
US20050256161A1 (en) * 2003-08-13 2005-11-17 Tempest Paul A Melanin concentrating hormone receptor antagonists
US7514438B2 (en) 2003-08-13 2009-04-07 Amgen, Inc. Melanin concentrating hormone receptor antagonist
AU2004265189B2 (en) * 2003-08-15 2010-03-04 Banyu Pharmaceutical Co., Ltd. Imidazopyridine derivatives
CA2540826A1 (en) 2003-10-01 2005-04-14 The Procter & Gamble Company Melanin concentrating hormone antagonists
WO2005039564A1 (en) * 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
WO2005035521A1 (en) * 2003-10-09 2005-04-21 Argenta Discovery Ltd. Substituted quinolines as mcr modulators
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10360745A1 (de) * 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
US20080161344A1 (en) * 2004-02-09 2008-07-03 Steenstra Cheryl K Melanin Concentrating Hormone Receptor Ligands: Substituted Tetrahydroisoquinoline Analogues
WO2005090340A1 (ja) * 2004-03-22 2005-09-29 Banyu Pharmaceutical Co., Ltd. ピペリジン－１－カルボキサミド誘導体
US20090036448A1 (en) * 2004-03-30 2009-02-05 Taisho Pharmecutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
EP1729762A4 (en) * 2004-03-31 2007-12-19 Neurogen Corp POLYTHERAPY FOR WEIGHT MANAGEMENT
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
DE102004017932A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
WO2005108370A1 (ja) * 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
WO2005123714A1 (en) * 2004-06-16 2005-12-29 7Tm Pharma A/S Quinazoline compounds and their use in mch-related disease
CN101891680B (zh) 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
US7521560B2 (en) * 2004-06-29 2009-04-21 Rigel Pharmaceuticals, Inc. 2-substituted quinoline compounds and their uses
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
JPWO2006104136A1 (ja) * 2005-03-29 2008-09-11 萬有製薬株式会社 非アルコール性脂肪性肝疾患の治療剤、及び非アルコール性脂肪性肝疾患の治療又は予防のための薬剤の候補化合物のスクリーニング方法
WO2007016292A2 (en) * 2005-07-27 2007-02-08 Vertex Pharmaceuticals Incorporated Heterocyclic amides as biofilm modulators
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
EP1923388A4 (en) 2005-08-12 2011-03-09 Takeda Pharmaceutical BRAIN / NEURONAL CELL PROTECTIVE AGENT AND THERAPEUTIC AGENT FOR SLEEP DISORDERS
EP1917245A1 (de) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
US20090176789A1 (en) * 2005-08-26 2009-07-09 Breslin Michael J Diazaspirodecane orexin receptor antagonists
WO2007039462A2 (en) 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Indane derivatives as mch receptor antagonists
CN101374849A (zh) * 2005-12-24 2009-02-25 沃泰克斯药物股份有限公司 作为abc转运蛋白调控剂的喹啉-4-酮衍生物
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
DE602007011897D1 (de) 2006-02-15 2011-02-24 Sanofi Aventis Neue aminoalkohol-substituierte aryldihydroisochinolinone, herstellungsverfahren und ihre verwendung als medikamente
US8178667B2 (en) * 2006-06-28 2012-05-15 Merck Sharp & Dohme Corp. Benzyl-substituted quinolone M1 receptor positive allosteric modulators
US20080058309A1 (en) * 2006-07-27 2008-03-06 Astrazeneca Ab Novel Compounds 171
ES2399071T3 (es) 2006-10-16 2013-03-25 Bionomics Limited Nuevos compuestos ansiolíticos
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
CA2681481A1 (en) * 2007-03-16 2008-09-25 Mount Sinai School Of Medicine Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction
WO2008114002A1 (en) 2007-03-22 2008-09-25 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases
TWI417099B (zh) 2007-03-23 2013-12-01 Neuraxon Inc 具抑制一氧化氮合成酶活性之喹諾酮、四氫喹啉及其相關化合物
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5647519B2 (ja) 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成
US8106073B2 (en) 2007-11-30 2012-01-31 Astrazeneca Ab Quinoline derivatives 057
KR100937738B1 (ko) * 2007-12-14 2010-01-21 한국과학기술연구원 퀴놀린 카복실산 아마이드 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 항균 조성물
KR20100119789A (ko) * 2008-03-07 2010-11-10 에프. 호프만-라 로슈 아게 2-아미노퀴놀린
WO2009123194A1 (ja) * 2008-04-01 2009-10-08 武田薬品工業株式会社 複素環化合物
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
CN102149697A (zh) * 2008-09-08 2011-08-10 弗·哈夫曼-拉罗切有限公司 作为5-ht-5a受体拮抗剂的6-取代的苯并*嗪
TW201026667A (en) * 2008-09-30 2010-07-16 Merz Pharma Gmbh & Co Kgaa Glycine b antagonists
TW201040154A (en) 2009-02-13 2010-11-16 Sanofi Aventis Novel substituted indanes, process for preparation thereof and use thereof as a medicament
UY32443A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
KR101727762B1 (ko) 2009-03-20 2017-04-17 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
EP2487175A1 (en) 2009-10-06 2012-08-15 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical product containing aromatic heterocyclic compound
WO2012037108A1 (en) * 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US20120165331A1 (en) * 2010-12-22 2012-06-28 Sangamesh Badiger Di/tri-aza-spiro-C9-C11alkanes
JP2014510065A (ja) * 2011-03-02 2014-04-24 バイオノミックス リミテッド 治療薬としての新規な小分子
JP6055817B2 (ja) 2011-05-12 2016-12-27 バイオノミックス リミテッド ナフチリジンの調製方法
EP2709609B1 (en) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterocyclic compounds
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
WO2013130943A1 (en) * 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
CA2900652C (en) 2013-02-15 2021-05-04 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN107915751A (zh) 2013-02-20 2018-04-17 卡拉制药公司 治疗性化合物和其用途
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015066482A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN103787992B (zh) * 2014-01-21 2016-04-20 华东理工大学 N,n-双取代苯并氮杂环-2-胺类化合物及其用途
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
WO2016196955A1 (en) * 2015-06-04 2016-12-08 Drexel University Inhibitors of RAD52 Recombination Protein and Methods Using Same
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
MX2019002629A (es) 2016-09-08 2019-10-07 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapéuticos y usos de los mismos.
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324716B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US12012394B2 (en) 2018-02-19 2024-06-18 Washington University Alpha-synuclein ligands
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
CN114269720B (zh) * 2019-07-25 2025-03-28 库拉德夫制药私人有限公司 乙酰辅酶a合成酶短链2(acss2)的小分子抑制剂

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743732A (en) * 1972-02-14 1973-07-03 Miles Lab Process for suppressing the tremor of parkinson's syndrome
JPS5933264A (ja) * 1982-07-24 1984-02-23 フアイザ−・コ−ポレ−シヨン ２−置換４−アミノ−６，７−ジメトキシキノリン
WO1994017066A1 (en) * 1993-01-27 1994-08-04 Merck & Co., Inc. 2-phenanthridinyl carbapenem antibacterial agents
WO1996006084A1 (en) * 1994-08-19 1996-02-29 C & C Research Labs. Novel quinolylamine derivative, process for production thereof, and use thereof as antiarrhythmic agent
JPH10316664A (ja) * 1997-05-01 1998-12-02 Pfizer Inc 治療に有用なキノリンおよびキナゾリン化合物
WO1999048492A1 (en) * 1998-03-26 1999-09-30 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
JPH11335355A (ja) * 1998-03-26 1999-12-07 Japan Tobacco Inc アミド誘導体及びノシセプチンアンタゴニスト
WO2000064877A1 (en) * 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
WO2000076984A2 (en) * 1999-05-21 2000-12-21 Biovitrum Ab Novel compounds, their use and preparation
WO2001010842A2 (en) * 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
JP2001064529A (ja) * 1999-08-26 2001-03-13 Konica Corp ハロゲン化銀カラー写真用発色現像主薬とそのプレカーサー、ハロゲン化銀カラー感光材料とその処理組成物、カラー画像形成方法、画像形成材料
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
JP2004536066A (ja) * 2001-05-21 2004-12-02 エフ．ホフマン−ラ　ロシュ　アーゲー ニューロペプチドｙレセプターのリガンドとしてのキノリン誘導体

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013665A (en) * 1973-10-01 1977-03-22 Bristol-Myers Company Antiviral, substituted 1,3-dimethyl-1h-pyrazolo(3,4b)quinolines
US4701459A (en) * 1986-07-08 1987-10-20 Bristol-Myers Company 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
US5488055A (en) 1995-03-10 1996-01-30 Sanofi Winthrop Inc. Substituted N-cycloalkylmethyl-1H-pyrazolo(3,4-b)quinolin-4 amines and compositions and methods of use thereof
AU5812498A (en) 1996-12-20 1998-07-17 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
AU9462098A (en) 1997-10-15 1999-05-03 Kyowa Hakko Kogyo Co. Ltd. Piperidine derivatives
EP1047691A1 (en) 1997-12-12 2000-11-02 Smithkline Beecham Plc Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
WO1999042464A1 (en) 1998-02-23 1999-08-26 Warner-Lambert Company SUBSTITUTED IMIDAZO[1,2-a;3,4-a']DIQUINOLINYLIUM INTERLEUKIN-8 RECEPTOR ANTAGONISTS
AU3344099A (en) 1998-04-17 1999-11-08 Kyowa Hakko Kogyo Co. Ltd. Analgetic agent
AU6159499A (en) 1998-09-29 2000-04-17 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
GB9827882D0 (en) 1998-12-17 1999-02-10 Smithkline Beecham Plc Novel compounds
BR9916827A (pt) * 1998-12-23 2001-10-16 Janssen Pharmaceutica Nv Derivados de quinolina 1,2-anelados
US6221613B1 (en) * 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
US6168579B1 (en) 1999-08-04 2001-01-02 Scimed Life Systems, Inc. Filter flush system and methods of use
US7115750B1 (en) * 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
WO2001021169A1 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Mch antagonists
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
CA2392507A1 (fr) 1999-11-29 2001-06-07 Aventis Pharma S.A. Derives arylamines et leur application comme agent antitelomerase
DK1242382T3 (da) 1999-12-29 2007-05-07 Wyeth Corp Tricycliske proteinkinaseinhibitorer
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
IL151249A0 (en) 2000-03-13 2003-04-10 American Cyanamid Co Use of cyanoquinolines for treating or inhibiting colonic polyps
AR028261A1 (es) 2000-03-28 2003-04-30 Wyeth Corp Inhibidores triciclicos de la proteina quinasa
ATE479429T1 (de) 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
JP2002371059A (ja) 2000-05-16 2002-12-26 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
EA200201119A1 (ru) 2000-06-28 2003-06-26 Пфайзер Продактс Инк. Лиганды меланокортиновых рецепторов
CA2384041A1 (en) 2000-07-05 2002-01-24 Synaptic Pharmaceuticals Corporation Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof
US6720324B2 (en) * 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
US6569861B2 (en) * 2000-07-06 2003-05-27 Neurogen Corporation Melanin concentrating hormone receptor ligands
IL155163A0 (en) * 2000-10-02 2003-10-31 Janssen Pharmaceutica Nv Metabotropic glutamate receptor antagonists
AU2002239291A1 (en) 2000-11-22 2002-06-03 Tularik, Inc. G protein coupled receptors
NZ525723A (en) 2000-12-22 2004-11-26 Schering Corp 1,4-di-substituted piperidine antagonists for melanin-concentrating hormone (MCH) and their use in the treatment of obesity or diabetes
CN1331864C (zh) * 2001-03-02 2007-08-15 神经研究公司 新型2,5－二氮杂二环[2.2.1]庚烷衍生物
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
KR20030093257A (ko) 2001-03-21 2003-12-06 파마코페이아, 인크. Ｍｃｈ 조정 활성을 지닌 아릴 및 바이아릴 화합물
ATE460163T1 (de) 2001-04-12 2010-03-15 Pharmacopeia Llc Arly und diaryl piperidinderivate verwendbar als mch-hemmer
WO2002089729A2 (en) 2001-05-04 2002-11-14 Tularik Inc. Fused heterocyclic compounds
IL158941A0 (en) 2001-05-22 2004-05-12 Neurogen Corp Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
US6727264B1 (en) * 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
IL159697A0 (en) 2001-07-05 2004-06-20 Synaptic Pharma Corp Substituted anilinic piperidines as mch selective antagonists
CA2456964A1 (en) 2001-08-08 2003-02-20 Merck & Co., Inc. Melanin-concentrating hormone antagonists
DE10139416A1 (de) 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2005508161A (ja) 2001-09-24 2005-03-31 メルク　エンド　カムパニー　インコーポレーテッド アカゲザル、イヌ及びフェレットメラニン凝集ホルモン１型受容体
JP2005508632A (ja) 2001-09-26 2005-04-07 メルク　エンド　カムパニー　インコーポレーテッド メラニン凝集ホルモン受容体アンタゴニスト結合タンパク質
AU2002334733B2 (en) 2001-10-01 2006-11-23 Arena Pharmaceuticals, Inc. MCH receptors antagonists
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
CN1585751A (zh) 2001-10-25 2005-02-23 武田药品工业株式会社 喹啉化合物
EP1443922A1 (en) 2001-10-25 2004-08-11 Schering Corporation Mch antagonists for the treatment of obesity
AR037429A1 (es) 2001-11-26 2004-11-10 Schering Corp Derivados de piperidina antagonistas de la mch, composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos derivados, solos o en combinacion, para la fabricacion de un medicamento para tratamiento de la obesidad y de trastornos del snc
EP1451156A4 (en) 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOCHINOLINVERBINDUNGEN
WO2003059289A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
US6818772B2 (en) 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
WO2003070244A1 (en) 2002-02-22 2003-08-28 Abbott Laboratories Antagonist of melanin concentrating hormone and their uses
AU2003226928A1 (en) 2002-04-09 2003-10-27 7Tm Pharma A/S Novel aminotetraline compounds for use in mch receptor related disorders
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
CA2482341A1 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel methoxybenzamide compounds for use in mch receptor related disorders
JP2005529923A (ja) 2002-05-13 2005-10-06 イーライ・リリー・アンド・カンパニー 肥満および糖尿病の治療におけるメラニン凝集ホルモンアンタゴニストとして使用するための多環式化合物
AU2003243497A1 (en) * 2002-06-12 2003-12-31 Millennium Pharmaceuticals, Inc. Antagonists of melanin concentrating hormone receptor
CA2490531C (en) 2002-06-27 2011-03-22 Schering Corporation Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
AU2003259131A1 (en) * 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743732A (en) * 1972-02-14 1973-07-03 Miles Lab Process for suppressing the tremor of parkinson's syndrome
JPS5933264A (ja) * 1982-07-24 1984-02-23 フアイザ−・コ−ポレ−シヨン ２−置換４−アミノ−６，７−ジメトキシキノリン
WO1994017066A1 (en) * 1993-01-27 1994-08-04 Merck & Co., Inc. 2-phenanthridinyl carbapenem antibacterial agents
WO1996006084A1 (en) * 1994-08-19 1996-02-29 C & C Research Labs. Novel quinolylamine derivative, process for production thereof, and use thereof as antiarrhythmic agent
JPH10316664A (ja) * 1997-05-01 1998-12-02 Pfizer Inc 治療に有用なキノリンおよびキナゾリン化合物
WO1999048492A1 (en) * 1998-03-26 1999-09-30 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
JPH11335355A (ja) * 1998-03-26 1999-12-07 Japan Tobacco Inc アミド誘導体及びノシセプチンアンタゴニスト
WO2000064877A1 (en) * 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
WO2000076984A2 (en) * 1999-05-21 2000-12-21 Biovitrum Ab Novel compounds, their use and preparation
WO2001010842A2 (en) * 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
JP2001064529A (ja) * 1999-08-26 2001-03-13 Konica Corp ハロゲン化銀カラー写真用発色現像主薬とそのプレカーサー、ハロゲン化銀カラー感光材料とその処理組成物、カラー画像形成方法、画像形成材料
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
JP2004536066A (ja) * 2001-05-21 2004-12-02 エフ．ホフマン−ラ　ロシュ　アーゲー ニューロペプチドｙレセプターのリガンドとしてのキノリン誘導体

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526723A (ja) * 2002-02-15 2005-09-08 グラクソ　グループ　リミテッド バニロイド受容体モジュレーター
JPWO2004103992A1 (ja) * 2003-05-21 2006-07-20 萬有製薬株式会社 ２−アミノキノリン誘導体
JP2009526793A (ja) * 2006-02-15 2009-07-23 サノフィ−アベンティス 新規なアザシクリル置換アリールジヒドロイソキノリノン、それらの製造方法及び薬剤としてそれらの使用
JP2010504939A (ja) * 2006-09-28 2010-02-18 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ結合性を有するキノリン誘導体
WO2009011336A1 (ja) * 2007-07-18 2009-01-22 Taisho Pharmaceutical Co., Ltd. キノリン化合物
JP2010540483A (ja) * 2007-09-27 2010-12-24 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ５ａ受容体アンタゴニストとしてのキノリン誘導体
JP2011513350A (ja) * 2008-03-05 2011-04-28 エフ．ホフマン−ラ ロシュ アーゲー ２−アミノキノリン類
JP2011513452A (ja) * 2008-03-12 2011-04-28 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ５ａ受容体アンタゴニストとしての２−アミノキノリン
JP2011518809A (ja) * 2008-04-24 2011-06-30 アボット ゲーエムベーハー ウント カンパニー カーゲー グリコーゲン合成酵素キナーゼ３（ｇｓｋ−３）としての１−（７−（ヘキサヒドロピロロ［３，４−ｃ］ピロール−２（１ｈ）−イル）キノリン−４−イル）−３−（ピラジン−２−イル）尿素誘導体とその関連化合物
JP2012528078A (ja) * 2009-05-29 2012-11-12 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体
US9522140B2 (en) 2009-05-29 2016-12-20 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
WO2014034719A1 (ja) * 2012-08-29 2014-03-06 興和株式会社 Ｔｌｒ阻害作用を有するキノリン誘導体
JPWO2014034719A1 (ja) * 2012-08-29 2016-08-08 興和株式会社 Ｔｌｒ阻害作用を有するキノリン誘導体
JP2023532332A (ja) * 2020-07-02 2023-07-27 リミックス セラピューティクス インコーポレイテッド 核酸のスプライシング及び増殖性疾患の処置のためのモジュレーターとしての２－（インダゾール－５－イル）－６－（ピペリジン－４－イル）－１，７－ナフチリジン誘導体及び関連する化合物

Also Published As

Publication number Publication date
US20050026915A1 (en) 2005-02-03
WO2003045313A2 (en) 2003-06-05
AU2002352878A1 (en) 2003-06-10
CA2468015A1 (en) 2003-06-05
WO2003045313A3 (en) 2003-09-04
EP1450801A2 (en) 2004-09-01
AU2002352878B2 (en) 2007-11-22
US7084156B2 (en) 2006-08-01
EP1450801A4 (en) 2010-10-27

Similar Documents

Publication Publication Date Title
US7084156B2 (en) 2-Aminoquinoline compounds
JP2005518365A (ja) ４−アミノキノリン化合物
JP4336196B2 (ja) メラノコルチン受容体作動薬としての架橋ピペリジン誘導体
US7998959B2 (en) Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
JP5435592B2 (ja) ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
US8293900B2 (en) Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2024019398A (ja) 置換ジアザヘテロ－二環式化合物およびそれらの使用
US20050054850A1 (en) Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
US20080004312A1 (en) Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
US20090258853A1 (en) Somatostatin Agonists
ES2293317T3 (es) Derivados de tetrahidroquinazolina com antagonistas de cfr.
US20090253744A1 (en) Acylated piperidine derivatives as melanocortin-4 receptor modulators
TW201132642A (en) Diaza-spiro[5.5]undecanes
WO2005035526A1 (en) Bicyclic compounds and their therapeutic use
KR20070114762A (ko) 염증 질환 치료를 위한 ｐｇｄ2 수용체 길항제
AU2007332867B2 (en) Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators
US7652024B2 (en) Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
TW200838516A (en) Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
CA2624031A1 (en) Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2005035521A1 (en) Substituted quinolines as mcr modulators
TWI764201B (zh) 可用為幾丁質酶抑制劑的經取代的胺基三唑
CN117624191A (zh) 吲唑甲酰胺类衍生物及其制备方法和用途
US7119107B2 (en) Pyridone derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090610

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100420

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101012